GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objectiv...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2018/4020492 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548340991000576 |
|---|---|
| author | María Isabel del Olmo-Garcia Juan Francisco Merino-Torres |
| author_facet | María Isabel del Olmo-Garcia Juan Francisco Merino-Torres |
| author_sort | María Isabel del Olmo-Garcia |
| collection | DOAJ |
| description | Diabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might show benefits on endothelial function, coronary ischaemia, and heart failure. On the other hand, recent clinical trials aimed at studying cardiovascular episodes have been conducted with GLP-1 RAs. Only liraglutide and semaglutide have shown superiority in cardiovascular benefit compared with placebo. Although many of the mechanisms by which liraglutide and semaglutide produce a cardiovascular benefit are still unknown it would be desirable for these benefits to be incorporated into the therapeutic algorithms routinely used in clinical practice. The purpose of this review is to explore GLP-1 RA actions not only in cardiovascular risk factors (glucose, weight, and hypertension) but also the possible effects on established cardiovascular disease. |
| format | Article |
| id | doaj-art-a0071b2ec456430fa37ebc9774e30990 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-a0071b2ec456430fa37ebc9774e309902025-02-03T06:14:20ZengWileyJournal of Diabetes Research2314-67452314-67532018-01-01201810.1155/2018/40204924020492GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 DiabetesMaría Isabel del Olmo-Garcia0Juan Francisco Merino-Torres1Mixed Endocrinology, Nutrition and Dietetics Research Unit, University Hospital La Fe, València, SpainMixed Endocrinology, Nutrition and Dietetics Research Unit, University Hospital La Fe, València, SpainDiabetes mellitus is a chronic disease prevalence of which is high and continually growing. Cardiovascular disease continues to be the leading cause of death in patients with T2DM. The prevention of cardiovascular complications and the cardiovascular safety of treatments should be a primary objective when selecting treatment. Among all the drugs available, the compounds known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) appear to be not just innocuous in terms of CVD but indeed to be beneficial. GLP-1 RA actions not only translate on an improvement of well-known cardiovascular risk factors such as glycaemic control, dyslipidaemia, weight, or arterial hypertension but also might show benefits on endothelial function, coronary ischaemia, and heart failure. On the other hand, recent clinical trials aimed at studying cardiovascular episodes have been conducted with GLP-1 RAs. Only liraglutide and semaglutide have shown superiority in cardiovascular benefit compared with placebo. Although many of the mechanisms by which liraglutide and semaglutide produce a cardiovascular benefit are still unknown it would be desirable for these benefits to be incorporated into the therapeutic algorithms routinely used in clinical practice. The purpose of this review is to explore GLP-1 RA actions not only in cardiovascular risk factors (glucose, weight, and hypertension) but also the possible effects on established cardiovascular disease.http://dx.doi.org/10.1155/2018/4020492 |
| spellingShingle | María Isabel del Olmo-Garcia Juan Francisco Merino-Torres GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes Journal of Diabetes Research |
| title | GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes |
| title_full | GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes |
| title_fullStr | GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes |
| title_full_unstemmed | GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes |
| title_short | GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes |
| title_sort | glp 1 receptor agonists and cardiovascular disease in patients with type 2 diabetes |
| url | http://dx.doi.org/10.1155/2018/4020492 |
| work_keys_str_mv | AT mariaisabeldelolmogarcia glp1receptoragonistsandcardiovasculardiseaseinpatientswithtype2diabetes AT juanfranciscomerinotorres glp1receptoragonistsandcardiovasculardiseaseinpatientswithtype2diabetes |